Sitemap

Posts

• Category: Acomplia Rimonabant, Zimulti News For 2008
  • (No Title)
    Diet drugs like Acomplia (rimonabant), Xenical and Meridia that patients may need to take for years require more study to see if they also help people live longer before doctors can be sure Acomplia (rimonabant) the benefits are greater than the risks, according to Canadian researchers writing in The Lancet. While Acomplia, which is not yet approved..
  • (No Title)
    Scientists have long believed that all Acomplia (rimonabant) addictions — from alcohol and drugs to smoking and binge-eating — were connected. In the past few years, laboratory tests have confirmed these theories, putting researchers closer to finding a single drug that would treat most addictions, according Acomplia (rimonabant)..
  • (No Title)
    One participant in the early Acomplia studies has recently reported on her experience in Newsweek magazine. When Karen Helmick got married in 1974, the 5-foot-4 blonde already tipped the scales at 165 pounds. By 2001 the pound-a-year creep had nudged her to 213. Then she heard about a trial of an experimental weight-loss drug called rimonabant...
  • (No Title)
    The L-Marc Research Center (Louisville Metabolic and Atheroscerosis Research Center) in Louisville, Kentucky, is one of the most active metabolic research centers in the world, focusing Acomplia (rimonabant) on Phase II-IV clinical trials of weight-loss drugs. The clinic is a leading recruiter of participants in weight-loss trials, and when it..
  • (No Title)
    Diet drug r Acomplia (rimonabant)  was approved for sale on April 3rd by Switzerland for treatment of obese or overweight patients with at least one type of associated cardiovascular risk. The approval by Switzerland, which is not a member of the European Union, is similar to the EU marketing approval last June, where the drug was cleared..
  • (No Title)
    A year ago at this time, millions of overweight and obese Americans were excitedly awaiting both a new prescription weight-loss drug, rimonabant (Acomplia / Zimulti) , and the first over-the-counter diet drug, Alli (low-dose Xenical), which were expected to be on the U.S. market by summer. But twelve disappointing months later, FDA approval of..
  • 600 European Patients to Be Enrolled in New Trial of Obesity Drug ATL-962
    A second Phase IIb clinical trial has been approved by British regulators to evaluate ATL-962 for the treatment of obesity in up to 600 clinically obese diabetic patients. The randomised, double-blind trial Acomplia (rimonabant) will compare three doses of ATL-962 with a placebo and with the obesity drug Xenical. Acomplia (rimonabant) Patients..
  • Acomplia Is ‘Product to Watch’ for 2007
    The magazine Med Ad News, in an article on “future blockbuster drugs,” has named Acomplia its “Product to Watch for 2005″ and said experts feel it has the potential to become the pharmaceutical industry’s once-in-a-decade blockbuster. Below are excerpts from its report: Acomplia’s potential resides in its..
  • Acomplia Report Newsletter Is Renamed the Zimulti Acomplia
    The Acomplia (rimonabant) since 2004 the only independent newsletter reporting on the development of diet drug Acomplia (rimonabant), announced today that effective immediately, the online newsletter will be named the Acomplia The name change was made after the U.S. Food and Drug Administration and manufacturer Sanofi-Aventis confirmed that..
  • After Initial Excitement, Unease Over Acomplia Side Effects
    Following the first wave of excitement over the latest trial data showing that obese and overweight people lose four times as much weight on Acomplia (rimonabant) as on a placebo, an undercurrent of unease has emerged over side effects that the researchers described as “mainly minor and short-lived.” The concern is fueled by the trial..
  • Amylin Weight-Loss Drug Shows Promise in Early Trial
    Amylin Pharmaceuticals on June 3rd presented early-stage results of a trial of their drug pramlintide that showed obese people lost an average of 7.7 pounds more than those taking a placebo, with no evidence that they were hitting a plateau at the end of the 16-week trial period Acomplia (rimonabant) . Pramlintide is a synthetic analog of human..
  • Business Week: Acomplia Approval by U.S. FDA “Isn’t a Slam Dunk”
    While Business Week magazine reports that Sanofi researchers “succeeded beyond their wildest dreams” in creation of Acomplia, the magazine reports in its December 27th issue that U.S. Food and Drug Administration approval of rimonabant for treatment of obesity and Acomplia (rimonabant)   tobacco addiction “isn’t a slam..
  • Commentary: Experts Still Not Sure Exactly What Acomplia Does
    The Baltimore Sun, in an editorial commenting on the excitement generated by promising results for the weight-loss drug Acomplia, cautions that “buyers should beware [ Acomplia (rimonabant) ] the experts are still not sure what exactly it does.” The commentary, which appeared on November 27th, notes that Acomplia “is the first..
  • Commentary: Mythology of Acomplia Plays to Magic Pill Approach to Health
    Mike Adams, a holistic nutritionist who has authored a number of books on nutrition, wellness, food toxicology and the causes of disease and health, has written the following commentary on the weight-loss drug Acomplia. The views are his own, and are reported because of the widespread interest in this subject. A new weight loss drug, Acomplia,..
  • Companies to Push Development of Nasal Spray for Treatment of Obesity
    Acomplia (rimonabant) Nastech Pharmaceutical Company Inc. and Merck & Co., Inc. announced that they have entered into a global alliance to develop and commercialize Peptide YY 3-36 Nasal Spray (PYY), Nastech’s Phase I product for the treatment of obesity. Under the agreement, Merck will assume primary responsibility for clinical and..
  • Competitor for Diet Drug Rimonabant (Acomplia) Now Has Name: Taranabant
    While Sanofi’s diet drug Acomplia (rimonabant) remains stalled at the FDA, a potential competitor currently in phase III trials, Merck’s MK-0364, now has an official generic name: Taranabant. Taranabant is Merck’s cannabinoid-1 (CB-1) receptor inverse agonist, and from reports we periodically receive from participants in the..
  • Concern Expressed That Acomplia May Up Risk of Ectopic (Tubal) Pregnancy
    Vanderbilt University researchers are expressing concern that the diet drug Acomplia (rimonabant)  may potentially increase the risk of ectopic pregnancies in young women, according to a report in the October issue of the journal Nature Medicine. Ectopic pregnancy occurs when a fertilized egg implants in tissue outside of the uterus, and..
  • Copies of Diet Drug Acomplia (Rimonabant)
    Copies of diet drug Acomplia ( rimonabant ) are being widely sold at Indian pharmacies without a prescription for as little as $3.60 for a month’s supply of the pill, according to reports from the Indian media. A half-dozen pharmaceutical companies — including such well-regarded generic drug manufacturers as Ranbaxy and Cipla —..
  • Diet Drug Acomplia (Rimonabant) Doubles Risk of Depression — European Regulators
    Taking diet drug Acomplia (rimonabant) approximately doubles your risk of depression, and the risk may be even higher if you have a past history of depression, according to the European Medicines Agency (EMEA). “ This doubling of the risk of depression occurs in all types of patients,” the EMEA’s Committee for Medicinal Products..